Pagkalos Ilias, Herrero Pau, Toumazou Christofer, Georgiou Pantelis
IEEE Trans Biomed Circuits Syst. 2014 Apr;8(2):186-95. doi: 10.1109/TBCAS.2014.2301377. Epub 2014 Mar 26.
This paper presents a bio-inspired method for in-vivo control of blood glucose based on a model of the pancreatic β-cell. The proposed model is shown to be implementable using low-power analogue integrated circuits in CMOS, realizing a biologically faithful implementation which captures all the behaviours seen in physiology. This is then shown to be capable of glucose control using an in silico population of diabetic subjects achieving 93% of the time in tight glycemic target (i.e., [70, 140] mg/dl) . The proposed controller is then compared with a commonly used external physiological insulin delivery (ePID) controller for glucose control. Results confirm equivalent, or superior, performance in comparison with ePID. The system has been designed in a commercially available 0.35 μm CMOS process and achieves an overall power consumption of 1.907 mW.
本文提出了一种基于胰腺β细胞模型的生物启发式体内血糖控制方法。所提出的模型被证明可以使用CMOS中的低功耗模拟集成电路来实现，实现了一种忠实于生物学的实现方式，该方式捕获了生理学中观察到的所有行为。然后表明，使用糖尿病患者的计算机模拟群体，该模型能够进行血糖控制，在严格的血糖目标（即[70, 140]mg/dl）下，93%的时间内都能达到目标。然后将所提出的控制器与常用的外部生理胰岛素输送（ePID）控制器进行血糖控制比较。结果证实，与ePID相比，该系统具有同等或更优的性能。该系统采用市售的0.35μm CMOS工艺设计，总功耗为1.907mW。
